|
4th Advanced Forum onBiotech PatentsThe Tactical and Practical Guide to Today's Most Complex IssuesMonday, December 06, 2004
AboutIn the ongoing quest to develop new, effective and profitable biological products and therapies, the biotech and pharmaceutical industries are constantly and aggressively fighting to preserve and enforce their patent rights to the existing tools and processes which continue to enable them to unlock the secrets of genetic defects and disease.However, innovator biotech companies are now about to face a whole new set of patent challenges. The patent life cycles of many of their most lucrative biological products are on the verge of expiration. Generic competitors are seeking to put biogenerics on the market in a manner similar to that of small molecule generic drugs. Although it is anyone's guess as to what the final outcome of these latest patent challenges will be, one thing is certain: based on the number of infringement suits filed in the last year alone, these companies will hold no bars to protect the patents on their biotech inventions. With millions in future revenue at stake, it is imperative that counsel to biotech and pharmaceutical companies and their advisors have an up-to-the-minute and complete understanding of the latest legal developments affecting biotech patents. This American Conference Institute publication will give you in-depth analysis from an outstanding faculty of leading in-house biotech and pharmaceutical counsel and expert attorneys. Contents & ContributorsAboutIn the ongoing quest to develop new, effective and profitable biological products and therapies, the biotech and pharmaceutical industries are constantly and aggressively fighting to preserve and enforce their patent rights to the existing tools and processes which continue to enable them to unlock the secrets of genetic defects and disease.However, innovator biotech companies are now about to face a whole new set of patent challenges. The patent life cycles of many of their most lucrative biological products are on the verge of expiration. Generic competitors are seeking to put biogenerics on the market in a manner similar to that of small molecule generic drugs. Although it is anyone's guess as to what the final outcome of these latest patent challenges will be, one thing is certain: based on the number of infringement suits filed in the last year alone, these companies will hold no bars to protect the patents on their biotech inventions. With millions in future revenue at stake, it is imperative that counsel to biotech and pharmaceutical companies and their advisors have an up-to-the-minute and complete understanding of the latest legal developments affecting biotech patents. This American Conference Institute publication will give you in-depth analysis from an outstanding faculty of leading in-house biotech and pharmaceutical counsel and expert attorneys. Contents & ContributorsTHE SCOPE OF PROTECTION UNDER THE "SAFE HARBOR" PROVISION OF THE HATCH-WAXMAN ACT AND THAT OF FOREIGN COUNTERPARTS; APPLICABILITY OF THE "SAFE HARBOR" PROVISION TO RESEARCH TOOL PATENTS; AND SECTION 271(g) AND THE IMPORTATION OF DATABrian D. Coggio, Orrick, Herrington & Sutcliffe LLP STRATEGIES FOR ENHANCING THE LIKELY ENFORCEABILITY OF PHARMACEUTICAL PATENTS IN VIEW OF RECENT FEDERAL CIRCUIT DECISIONS David J. Weitz, Syrrx, Inc. Elizabeth A. Howard, Orrick, Herrington & Sutcliffe LLP Rachel D. Albright, Orrick, Herrington & Sutcliffe LLP PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT IN VIEW OF RECENT FEDERAL CIRCUIT DECISIONS Rachel D. Albright, Orrick, Herrington & Sutcliffe LLP PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT IN VIEW OF RECENT FEDERAL CIRCUIT DECISIONS David J. Weitz, Syrrx, Inc. FESTO IN LIGHT OF THE FEDERAL CIRCUIT'S EN BANC RULING: WHERE ARE WE NOW AND WHERE ARE WE GOING? Scott B. Familant, Orrick, Herrington & Sutcliffe LLP FOLLOW-ON BIOLOGICS: THE LEGAL AND REGULATORY LANDSCAPE Michael S. Labson, Covington & Burling ANTIBODY PATENTABILITY Jane T. Gunnison, Fish & Neave RESEARCH TOOL PATENTS: DEFENSES TO INFRINGEMENT Richard J. Berman, Arent Fox PLLC REACH-THROUGH CLAIMS Frank P. Grassler, GlaxoSmithKline JUDICIAL REMEDIES FOR INFRINGEMENT OF RESEARCH TOOL PATENTS Donald R. Ware, Foley Hoag LLP TACKLING WRITTEN DESCRIPTION ISSUES Gerard F. Diebner, Greenberg Traurig LLP CURRENT WRITEN DESCRIPTION REQUIREMENTS FOR PATENTABILITY IN BIOTECH Vernon M. Winters, Weil, Gotshal & Manges LLP CLAIM CONSTRUCTION TRENDS Sandra A. Bresnick, Weil Gotshal & Manges, LLP THE ACCIDENTAL AND INHERENT ANTICIPATION DOCTRINE: WHERE DO WE STAND AND WHERE ARE WE GOING? Anne Brown, Athersys Inc. Mark Polyakov, Athersys Inc. DOUBLE PATENTING: HANDLING DIFFICULT PROSECUTION AND LITIGATION ISSUES Emily A. Evans, Morrison & Foerster Jill A. Jacobson, Morrison & Foerster THE FINE ART OF INTERFERENCE PRACTICE: STRUCTURE, CONCEPTS AND PITFALLS Samuel B. Abrams, Jones Day LLP Muna Abu-Shaar, Jones Day LLP Christine B. Chua, Jones Day LLP THE ENABLEMENT REQUIREMENT AND FUTURE DEVELOPMENTS Kevin L. Bastian, Townsend Townsend & Crew LLP THE UTILITY REQUIREMENT AND THE GENOMICS INDUSTRY: A STUDY IN THE RELATIONSHIP BETWEEN COMMERCE AND LAW John Storella, Ciphergen 3D STRUCTURES & THE TRILATERAL REPORT Lisa A. Dixon, Vertex Pharmaceuticals Incorporated LICENSING STRATEGIES Judith Ann Hasko, Cooley Godward RECENT INTERNATIONAL AND DOMESTIC DEVELOPMENTS IN ANTITRUST, PATENT MISUSE AND COMPETITION LAW AFFECTING BIOTECH PATENT LICENSING Stephen P. Johnson, Kirkland & Ellis FREEDOM TO OPERATE AND OPINION LETTERS: KEY CONSIDERATIONS IN AN EVOLVING BIOTECH PATENT LANDSCAPE Joyce Morrison, Xencor Robin M. Silva, Dorsey & Whitney DRAFTING SUCCESSFUL BIOTECHNOLOGY RELATED PATENT APPLICATIONS – MASTER CLASS Mark A. Kassel, Foley Lardner Kenneth H. Sonnenfeld, Ph.D., J.D., Morgan & Finnegan Carol Stratford, Ph.D., J.D., Stratford Law |
Date: Mon, Dec 06, 2004 Location:
San Francisco, CA Pricing:
Option 1: Bundle Package
Binder & CD-ROM Save 299 - Best Value! Total: $699 + $9.95 (shipping & handling) + applicable taxes Option 2: CD-ROM
CD-ROM of program proceedings Total: $499 + $9.95 (shipping & handling) + applicable taxes Option 3: Binder
Printed copy of program proceedings Total: $499 + $9.95 (shipping & handling) |
 |
Publication Details |
Copyright 2007 C5 Group Inc. All Rights Reserved. |